Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.

ABSTRACT:

Objective

To determine the efficacy and safety of fremanezumab administration in Japanese and Korean patients with chronic migraine (CM).

Background

Available preventive treatments for CM are limited by various efficacy and safety issues. Fremanezumab, a monoclonal antibody that targets the calcitonin gene-related peptide pathway involved in migraine pathogenesis, has been shown to be effective and well tolerated in large-scale, international Phase 3 trials.

Methods

Randomized, placebo-controlled trial of patients with CM who received subcutaneous fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), fremanezumab quarterly (675 mg at baseline and placebo at weeks 4 and 8), or matching placebo. Primary endpoint was the mean change from baseline in the

SUBMITTER: Sakai F 

PROVIDER: S-EPMC8456899 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature